What is NDC 61703-319?

61703-319 is the product NDC for Cytarabine, Cytarabine 100 mg/mL injection, solution, listed with the FDA by Hospira, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Hospira, Inc., NDC labeler code 61703. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Cytarabine?

13 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Cytarabine NDC 61703-319 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)61703-319Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61703-0319Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61703-319-22	6170303192261703031922	1 VIAL, SINGLE-DOSE in 1 CARTON (61703-319-22) / 20 mL in 1 VIAL, SINGLE-DOSEMarketed from Nov 22, 1999

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cytarabine
Generic name (nonproprietary): cytarabine
Active ingredients: Cytarabine — 100 mg/mL
Dosage form: Injection, Solution
Route: Intrathecal, Intravenous, Subcutaneous
Labeler: Hospira, Inc.NDC labeler code 61703
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075383
Marketing start: Nov 22, 1999
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 61703-319_8365cd1f-0269-49a5-a86a-8122307c3659SPL ID 8365cd1f-0269-49a5-a86a-8122307c3659
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N461703031922 followed by a unit qualifier and the quantity

Package 61703-0319-22. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 61703-319

What is NDC 61703-319?: 61703-319 is the product NDC for Cytarabine, Cytarabine 100 mg/mL injection, solution, listed with the FDA by Hospira, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Cytarabine.
What is the active ingredient?: Cytarabine.
Who is the labeler?: Hospira, Inc., NDC labeler code 61703. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Cytarabine?: 13 other product NDCs are listed under this name. See all Cytarabine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Cytarabine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Cytarabine	Cytarabine 100 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Hospira, Inc.	61703-155	61703-0155-01
cytarabine	Cytarabine 100 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Sagent Pharmaceuticals	25021-223	25021-0223-20
cytarabine	Cytarabine 20 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Sagent Pharmaceuticals	25021-229	25021-0229-05
Cytarabine	Cytarabine 20 mg/mL	Injection, SolutionIntravenous, Subcutaneous	Meitheal Pharmaceuticals Inc.	71288-169	71288-0169-25
Cytarabine	Cytarabine 20 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Meitheal Pharmaceuticals Inc.	71288-108	71288-0108-06
Cytarabine	Cytarabine 100 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Gland Pharma Limited	68083-337	68083-0337-01
Cytarabine	Cytarabine 20 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Gland Pharma Limited	68083-343	68083-0343-05
Cytarabine	Cytarabine 2 g/20mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Meitheal Pharmaceuticals Inc.	71288-109	71288-0109-20
Cytarabine	Cytarabine 20 mg/mL	Injection, SolutionIntravenous, Subcutaneous	Meitheal Pharmaceuticals Inc.	71288-168	71288-0168-50
Cytarabine	Cytarabine 100 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Fresenius Kabi USA, LLC	63323-120	63323-0120-20

All 14 Cytarabine NDCs

Other NDCs under ANDA 075383

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075383
Product	Strength	Form · route	Labeler	Product NDC
Cytarabine	Cytarabine 100 mg/mL	Injection, SolutionIntrathecal, Intravenous, Subcutaneous	Hospira, Inc.	61703-155